Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 3Phase 3 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Radium-223 × Clear all
NCT04109729 2026-06-01

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03737370 2025-10-07

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Tufts Medical Center

Phase 1 Completed
43 enrolled
Genitourinary

Prostatic Neoplasms

NCT02406521 2020-03-04

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Dana-Farber Cancer Institute

Phase 1 Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡